Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns

Oncology

Volumn 64, Issue 4, 2003, Pages 407-415

  Yamamoto, Tetsuya ^a   Kimura, Tsuyoshi ^a   Ueta, Eisaku ^a   Tatemoto, Yukihiro ^a   Osaki, Tokio ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Chemo radio immunotherapy; Cytokines; Cytotoxicity; Oral cancer; Tumor infiltrating lymphocytes

Indexed keywords

COBALT 60; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEPLEOMYCIN; PICIBANIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA CELL; CYTOKINE PRODUCTION; CYTOTOXICITY; DAUDI CELL; GINGIVA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; BIOSYNTHESIS; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; RADIOTHERAPY, ADJUVANT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038312244     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070300     Document Type: Article

References (45)

1. Schuster N, Krieglstein K: Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002;307:1-14.
2. Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377.
3. Yoneda K, Yamamoto T, Ueta E, Osaki T: Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-γ in oral cancer patients. J Clin Immunol 1992;12:289-299.
4. Beatty GL, Paterson Y: Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol Res 2001;24:201-210.
5. Dalgleish AG: The role of IL-2 in gene therapy. Gene Ther 1994;1:83-87.
6. + effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 1999;162:3202-3211.
7. Derynck R, Akhurst RJ, Balmain A: TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
8. Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WK, Kang JK: Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-β treatment at early stage of tumor development. Clin Cancer Res 2000;6:3354-3360.
9. Nakajima I, Chu TM: Enhanced cell-mediated cytotoxicity by interferon-γ and interleukin-2 against syngeneic murine mammary adenocarcinoma. Mol Biother 1992;4:47-52.
10. Tzai TS, Lin SN: Interferon-α can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol 1992;147:523-527.
11. Keene JA, Forman J: Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-782.
12. + CTL. J Immunol 2001;167:3687-3691.
13. Partridge M, Chantry D, Turner M, Feldmann M: Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. J Invest Dermatol 1991;96:771-776.
14. Mann EA, Spiro JD, Chen LL, Kreutzer DL: Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 1992;164:567-573.
15. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, Bukowski RM: Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-785.
16. Hirabayashi H, Yasumura S, Lin WC, Amoscato A, Johnson JT, Herberman RB, Whiteside TL: Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells. Arch Otolaryngol Head Neck Surg 1995;121:285-292.
17. + renal-cell-carcinoma-infiltrating lymphocytes. Cancer Immunol Immunother 1999;48:204-208.
18. Csiszar A, Szentes T, Haraszti B, Zou W, Emilie D, Petranyi G, Pocsik E: Characterisation of cytokine mRNA expression in tumour-infiltrating mononuclear cells and tumour cells freshly isolated from human colorectal carcinomas. Eur Cytokine Netw 2001;12:87-96.
19. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol 1998;16:137-161.
20. Specht C, Bexten S, Kolsch E, Pauels HG: Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. Int J Cancer 2001;91:705-712.
21. Mann EA, Hibbs MS, Spiro JD, Bowik C, Wang XZ, Clawson M, Chen LL: Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma: The role of tumor necrosis factor-α. Ann Otol Rhinol Laryngol 1995;104:203-209.
22. Yoneda K, Osaki T, Yamamoto T, Ueta E: Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes. Clin Exp Immunol 1993;93:229-236.
23. Sasiain MC, de la Barrera S, Fink S, Finiasz M, Aleman M, Farina MH, Pizzariello G, Valdez R: Interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD. Clin Exp Immunol 1998;114:196-203.
24. Carter LL, Dutton RW: Type 1 and type 2: A fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 1996;8:336-342.
25. Croft M, Carter L, Swain SL, Dutton RW: Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715-1728.
26. Romagnani S: Biology of human TH1 and TH2 cells. J Clin Immunol 1995;15:121-129.
27. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
28. Shibata M, Nezi T, Takekawa M, Takizawa H, Ando K, Miyake H, Amano S, Kurosu Y: Serum levels of interleukin-10 and interleukin-12 in patients with colorectal cancer. Ann NY Acad Sci 1996;795:410-412.
29. 2-microglobulin in breast cancer patients. Tumour Biol 1995;16:290-296.
30. Yamamoto T, Yoneda K, Ueta E, Tatemoto Y, Osaki T: Combination adoptive immunotherapy with chemoradiotherapy in oral carcinomas. Int J Clin Oncol 1996;1:150-156.
31. Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V: Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986;90:221-233.
32. Gochi A, Orita K, Fuchimoto S, Tanaka N, Ogawa N: The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 2001;84:443-451.
33. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000;6:4663-4673.
34. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-282.
35. Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001;19:148-154.
36. Schondorf T, Engel H, Lindemann C, Kolhagen H, von Rucker AA, Mallmann P: Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol Immunother 1997;44:88-96.
37. + T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer 1997;71:178-182.
38. Khwaja A, Linch DC: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on neutrophil formation and function. Curr Opin Hematol 1994;1:216-220.
39. Semenzato G: Tumour necrosis factor: A cytokine with multiple biological activities. Br J cancer 1990;61:354-361.
40. Lawrence DA: Transforming growth factor-β: A general review. Eur Cytokine Netw 1996;7:363-374.
41. Patel P, Varghese E, Ding G, Fan S, Kapasi A, Reddy K, Franki N, Nahar N, Singhal P: Transforming growth factor β induces mesangial cell apoptosis through NO- and p53-dependent and -independent pathways. J Investig Med 2000;48:403-410.
42. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, Park CS, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H: Synergy of IL-12 and IL-18 for IFN-γ gene expression: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002;168:1146-1153.
43. Nakamura H, Ishiguro K, Mori T: Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer 1998;62:2489-2497.
44. Viale M, Ferrini S, Serrano S, Serrano D, Ardizzoni A, Nicolin A: Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: Analysis at the population and clonal level. Tumori 1990;76:488-494.
45. Oka M, Hazama S, Suzuki M, Ogura Y, Kobayashi N, Suzuki T: Histological analysis of hepatocellular carcinoma treated by intraarterial combined immunochemotherapy. Hepatogastroenterology 1995;42:561-566.